- Home
- COCH vs ALRN Comparison
COCH vs ALRN Comparison
Compare COCH & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- ALRN
- Stock Information
- Founded
- COCH 1995
- ALRN 2001
- Country
- COCH United States
- ALRN United States
- Employees
- COCH N/A
- ALRN N/A
- Industry
- COCH Blank Checks
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- ALRN Health Care
- Exchange
- COCH Nasdaq
- ALRN Nasdaq
- Market Cap
- COCH 64.4M
- ALRN 76.9M
- IPO Year
- COCH N/A
- ALRN 2017
- Fundamental
- Price
- COCH $2.08
- ALRN $3.42
- Analyst Decision
- COCH Strong Buy
- ALRN Strong Buy
- Analyst Count
- COCH 4
- ALRN 1
- Target Price
- COCH $7.92
- ALRN $19.00
- AVG Volume (30 Days)
- COCH 669.9K
- ALRN 93.8K
- Earning Date
- COCH 11-14-2024
- ALRN 11-26-2024
- Dividend Yield
- COCH N/A
- ALRN N/A
- EPS Growth
- COCH N/A
- ALRN N/A
- EPS
- COCH N/A
- ALRN N/A
- Revenue
- COCH $302,000.00
- ALRN N/A
- Revenue This Year
- COCH N/A
- ALRN N/A
- Revenue Next Year
- COCH $17.09
- ALRN N/A
- P/E Ratio
- COCH N/A
- ALRN N/A
- Revenue Growth
- COCH 38.53
- ALRN N/A
- 52 Week Low
- COCH $0.75
- ALRN $1.57
- 52 Week High
- COCH $11.46
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- COCH 34.73
- ALRN 47.41
- Support Level
- COCH $1.88
- ALRN $3.37
- Resistance Level
- COCH $2.28
- ALRN $3.92
- Average True Range (ATR)
- COCH 0.28
- ALRN 0.35
- MACD
- COCH -0.02
- ALRN -0.06
- Stochastic Oscillator
- COCH 20.44
- ALRN 21.36
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.